<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>REGLAN - metoclopramide hydrochloride tablet </strong><br>STAT RX USA LLC<br></p></div>
<h1>reglan<span class="Sup">®</span> tablets (metoclopramide tablets, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx Only</span></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-2"></a><p></p>
<h1><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">TARDIVE DYSKINESIA</span></span></h1>
<p class="First"><span class="Bold">Treatment with metoclopramide can cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, a serious <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span> that is often irreversible. The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> increases with duration of treatment and total cumulative dose.</span></p>
<p><span class="Bold">Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. There is no known treatment for <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.</span></p>
<p><span class="Bold">Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>.</span></p>
<p><span class="Bold">See <a href="#warn">WARNINGS</a></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">For oral administration, reglan<span class="Sup">®</span> tablets (metoclopramide tablets, USP) 10 mg are white, scored, capsule-shaped tablets engraved "REGLAN" on one side and "AP 10" on the opposite side.</p>
<p>Each tablet contains:<br>Metoclopramide base .................................................. 10 mg<br>(as the monohydrochloride monohydrate)</p>
<p><span class="Bold">Inactive Ingredients</span><br>Magnesium Stearate, Mannitol, Microcrystalline Cellulose, Stearic Acid.</p>
<p>reglan<span class="Sup">®</span> tablets (metoclopramide tablets, USP) 5 mg are green, elliptical-shaped tablets engraved "REGLAN" over "5" on one side and "AP" on the opposite side.</p>
<p>Each tablet contains:<br>Metoclopramide base .................................................... 5 mg<br>(as the monohydrochloride monohydrate)</p>
<p><span class="Bold">Inactive Ingredients</span><br>Corn starch, D&amp;C Yellow 10 Aluminum Lake, FD&amp;C Blue 1 Aluminum Lake, Lactose, Microcrystalline Cellulose, Silicon Dioxide, Stearic Acid.</p>
<p>Metoclopramide hydrochloride is a white crystalline, odorless substance, freely soluble in water. Chemically, it is 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy benzamide monohydrochloride monohydrate. Its molecular formula is C<span class="Sub">14</span>H<span class="Sub">22</span>ClN<span class="Sub">3</span>O<span class="Sub">2</span>•HCl•H<span class="Sub">2</span>O. Its molecular weight is 354.3.</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=55f1ee88-a455-44ba-b51a-2fcefe8eda65&amp;name=reglan-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clin"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not dependent on intact vagal innervation, but it can be abolished by anticholinergic drugs.</p>
<p>Metoclopramide increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit. It increases the resting tone of the lower esophageal sphincter. It has little, if any, effect on the motility of the colon or gallbladder.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span> and low LESP (lower esophageal sphincter pressure), single oral doses of metoclopramide produce dose-related increases in LESP. Effects begin at about 5 mg and increase through 20 mg (tile largest dose tested). The increase in LESP from a 5 mg dose lasts about 45 minutes and that of 20 mg lasts between 2 and 3 hours. Increased rate of stomach emptying has been observed with single oral doses of 10 mg.</p>
<p>The antiemetic properties of metoclopramide appear to be a result of its antagonism of central and peripheral dopamine receptors. Dopamine produces <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> by stimulation of the medullary chemoreceptor trigger zone (CTZ), and metoclopramide blocks stimulation of the CTZ by agents like l-dopa or apomorphine which are known to increase dopamine levels or to possess dopamine-like effects. Metoclopramide also abolishes the slowing of gastric emptying caused by apomorphine.</p>
<p>Like the phenothiazines and related drugs, which are also dopamine antagonists, metoclopramide produces sedation and may produce extrapyramidal reactions, although these are comparatively rare (see <span class="Bold"><a href="#warn">WARNINGS</a></span>). Metoclopramide inhibits the central and peripheral effects of apomorphine, induces release of prolactin and causes a transient increase in circulating aldosterone levels, which may be associated with transient <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
<p>The onset of pharmacological action of metoclopramide is 1 to 3 minutes following an intravenous dose, 10 to 15 minutes following intramuscular administration, and 30 to 60 minutes following an oral dose; pharmacological effects persist for 1 to 2 hours.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="pharma"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Metoclopramide is rapidly and well absorbed. Relative to an intravenous dose of 20 mg, the absolute oral bioavailability of metoclopramide is 80% ± 15.5% as demonstrated in a crossover study of 18 subjects. Peak plasma concentrations occur at about 1 to 2 hr after a single oral dose. Similar time to peak is observed after individual doses at steady state.</p>
<p>In a single dose study of 12 subjects, the area under the drug concentration-time curve increases linearly with doses from 20 to 100 mg. Peak concentrations increase linearly with dose; time to peak concentrations remains the same; whole body clearance is unchanged; and the elimination rate remains the same. The average elimination half-life in individuals with normal renal function is 5 to 6 hr. Linear kinetic processes adequately describe the absorption and elimination of metoclopramide.</p>
<p>Approximately 85% of the radioactivity of an orally administered dose appears in the urine within 72 hr. Of the 85% eliminated in the urine, about half is present as free or conjugated metoclopramide.</p>
<p>The drug is not extensively bound to plasma proteins (about 30%). The whole body volume of distribution is high (about 3.5 L/kg) which suggests extensive distribution of drug to the tissues.</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> affects the clearance of metoclopramide. In a study with patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, a reduction in creatinine clearance was correlated with a reduction in plasma clearance, renal clearance, non-renal clearance, and increase in elimination half-life. The kinetics of metoclopramide in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> remained linear however. The reduction in clearance as a result of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> suggests that adjustment downward of maintenance dosage should be done to avoid drug accumulation.</p>
<a name="ie8d9cd83-d19a-4274-8dee-cbf08db0723c"></a><table width="70%">
<caption><span>Adult Pharmacokinetic Data</span></caption>
<col align="left" valign="top" width="70%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th align="left">Parameter</th>
<th align="center">Value</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td align="left">Vd (Lkg)</td>
<td align="center">- 3.5</td>
</tr>
<tr class="Botrule">
<td align="left">Plasma Protein Binding</td>
<td align="center">- 30%</td>
</tr>
<tr class="Botrule">
<td align="left">t<span class="Sub">1/2</span> (hr)</td>
<td align="center">5 to 6</td>
</tr>
<tr class="Last">
<td align="left">Oral Bioavailability</td>
<td align="center">80% ± 15.5%</td>
</tr>
</tbody>
</table>
<p>In pediatric patients, the pharmacodynamics of metoclopramide following oral and intravenous administration are highly variable and a concentration-effect relationship has not been established.</p>
<p>There are insufficient reliable data to conclude whether the pharmacokinetics of metoclopramide in adults and the pediatric population are similar. Although there are insufficient data to support the efficacy of metoclopramide in pediatric patients with symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span> (GER) or cancer chemotherapy-related <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, its pharmacokinetics have been studied in these patient populations.</p>
<p>In an open-label study, six pediatric patients (age range, 3.5 weeks to 5.4 months) with GER received metoclopramide 0.15 mg/kg oral solution every 6 hours for 10 doses. The mean peak plasma concentration of metoclopramide after the tenth dose was 2-fold (56.8 µg/L) higher compared to that observed after the first dose (29 µg/L) indicating drug accumulation with repeated dosing. After the tenth dose, the mean time to reach peak concentrations (2.2 hr), half-life (4.1 hr), clearance (0.67 L/h/kg), and volume of distribution (4.4 L/kg) of metoclopramide were similar to those observed after the first dose. In the youngest patient (age, 3.5 weeks), metoclopramide half-life after the first and the tenth dose (23.1 and 10.3 hr, respectively) was significantly longer compared to other infants due to reduced clearance. This may be attributed to immature hepatic and renal systems at birth.</p>
<p>Single intravenous doses of metoclopramide 0.22 to 0.46 mg/kg (mean, 0.35 mg/kg) were administered over 5 minutes to 9 pediatric cancer patients receiving chemotherapy (mean age, 11.7 years; range, 7 to 14 yr) for prophylaxis of cytotoxic-induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. The metoclopramide plasma concentrations extrapolated to time zero ranged from 65 to 395 µg/L (mean, 152 µg/L). The mean elimination half-life, clearance, and volume of distribution of metoclopramide were 4.4 hr (range, 1.7 to 8.3 hr), 0.56 L/h/kg (range, 0.12 to 1.20 L/h/kg), and 3.0 L/kg (range, 1.0 to 4.8 L/kg), respectively.</p>
<p>In another study, nine pediatric cancer patients (age range, 1 to 9 yr) received 4 to 5 intravenous infusions (over 30 minutes) of metoclopramide at a dose of 2 mg/kg to control <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>. After the last dose, the peak serum concentrations of metoclopramide ranged from 1060 to 5680 µg/L. The mean elimination half-life, clearance, and volume of distribution of metoclopramide were 4.5 hr (range, 2.0 to 12.5 hr), 0.37 L/h/kg (range, 0.10 to 1.24 L/h/kg), and 1.93 L/kg (range, 0.95 to 5.50 L/kg), respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="usage"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">The use of reglan<span class="Sup">®</span> tablets is recommended for adults only. Therapy should not exceed 12 weeks in duration.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux</span></h2>
<p class="First">reglan<span class="Sup">®</span> tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span> who fail to respond to conventional therapy.</p>
<p>The principal effect of metoclopramide is on symptoms of postprandial and daytime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcers</span> and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">Diabetic Gastroparesis</span> (Diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">Gastric Stasis</span>)</h2>
<p class="First">reglan<span class="Sup">®</span> tablets (metoclopramide tablets, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">gastric stasis</span>. The usual manifestations of <span class="product-label-link" type="condition" conceptid="4010028" conceptname="Impaired gastric emptying">delayed gastric emptying</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, persistent fullness after meals, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>) appear to respond to reglan<span class="Sup">®</span> within different time intervals. Significant relief of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> occurs early and continues to improve over a three-week period. Relief of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> may precede the relief of <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal fullness</span> by one week or more.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contra"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Metoclopramide should not be used whenever stimulation of gastrointestinal motility might be dangerous, e.g., in the presence of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, mechanical obstruction, or perforation.</p>
<p>Metoclopramide is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span> because the drug may cause a <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>, probably due to release of catecholamines from the tumor. Such hypertensive crises may be controlled by phentolamine.</p>
<p>Metoclopramide is contraindicated in patients with known sensitivity or intolerance to the drug.</p>
<p>Metoclopramide should not be used in epileptics or patients receiving other drugs which are likely to cause extrapyramidal reactions, since the frequency and severity of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or extrapyramidal reactions may be increased.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warn"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> has occurred in patients with and without prior history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. Symptoms have ranged from mild to severe and have included <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. Metoclopramide should be given to patients with a prior history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> only if the expected benefits outweigh the potential risks.</p>
<p><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal symptoms</span>, manifested primarily as acute <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses. These symptoms may include involuntary movements of limbs and facial <span class="product-label-link" type="condition" conceptid="4221082" conceptname="Grimaces">grimacing</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, rhythmic protrusion of tongue, bulbar type of speech, <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>, or <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span> resembling <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>. Rarely, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span> may present as <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, possibly due to <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>. If these symptoms should occur, inject 50 mg diphenhydramine hydrochloride intramuscularly, and they usually will subside. Benztropine mesylate, 1 to 2 mg intramuscularly, may also be used to reverse these reactions.</p>
<p>Parkinsonian-like symptoms have occurred, more commonly within the first 6 months after beginning treatment with metoclopramide, but occasionally after longer periods. These symptoms generally subside within 2 to 3 months following discontinuance of metoclopramide. Patients with preexisting Parkinson's disease should be given metoclopramide cautiously, if at all, since such patients may experience exacerbation of parkinsonian symptoms when taking metoclopramide.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="tardive"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></h2>
<p class="First"><span class="Bold">(see <a href="#BOX">Boxed Warnings</a>)</span></p>
<p>Treatment with metoclopramide can cause <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> (TD), a potentially irreversible and disfiguring disorder characterized by involuntary movements of the face, tongue, or extremities. Although the risk of TD with metoclopramide has not been extensively studied, one published study reported a TD prevalence of 20% among patients treated for at least 12 weeks. Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing TD.</p>
<p>Although the risk of developing TD in the general population may be increased among the elderly, women, and diabetics, it is not possible to predict which patients will develop metoclopramide-induced TD. Both the risk of developing TD and the likelihood that TD will become irreversible increase with duration of treatment and total cumulative dose.</p>
<p>Metoclopramide should be discontinued in patients who develop signs or symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients, TD may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn.</p>
<p>Metoclopramide itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. Therefore, metoclopramide should not be used for the symptomatic control of TD.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS)</h2>
<p class="First">There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS) associated with metoclopramide. Clinical manifestations of NMS include <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered consciousness, and evidence of <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>).</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="440285" conceptname="Malignant hyperthermia">malignant hyperthermia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span> and primary central nervous system (CNS) pathology.</p>
<p>The management of NMS should include 1) immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. Bromocriptine and dantrolene sodium have been used in treatment of NMS, but their effectiveness have not been established (see <span class="Bold"><a href="#adverse">ADVERSE REACTIONS</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precau"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Because metoclopramide produces a transient increase in plasma aldosterone, certain patients, especially those with cirrhosis or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, may be at risk of developing <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and volume overload. If these side effects occur at any time during metoclopramide therapy, the drug should be discontinued.</p>
<p>Adverse reactions, especially those involving the nervous system, may occur after stopping the use of reglan<span class="Sup">®</span>. A small number of patients may experience a withdrawal period after stopping reglan<span class="Sup">®</span> that could include <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and/or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="info"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">The use of reglan<span class="Sup">®</span> is recommended for adults only. Metoclopramide may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle. The ambulatory patient should be cautioned accordingly.</p>
<p>For additional information, patients should be instructed to see the <a href="#medguide">Medication Guide</a> for reglan<span class="Sup">®</span> tablets.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.</p>
<p>The finding that metoclopramide releases catecholamines in patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> suggests that it should be used cautiously, if at all, in patients receiving monoamine oxidase inhibitors.</p>
<p>Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).</p>
<p><span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">Gastroparesis</span> (<span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">gastric stasis</span>) may be responsible for poor diabetic control in some patients. Exogenously administered insulin may begin to act before food has left the stomach and lead to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A 77-week study was conducted in rats with oral doses up to about 40 times the maximum recommended human daily dose. Metoclopramide elevates prolactin levels and the elevation persists during chronic administration. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent <span class="Italics">in vitro</span>, a factor of potential importance if the prescription of metoclopramide is contemplated in a patient with previously detected breast cancer. Although disturbances such as <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported with prolactin-elevating drugs, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of prolactin-stimulating neuroleptic drugs and metoclopramide. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is too limited to be conclusive at this time.</p>
<p>An Ames mutagenicity test performed on metoclopramide was negative.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>Pregnancy Category B</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.5.1"></a><p></p>
<h3></h3>
<p class="First">Reproduction studies performed in rats, mice and rabbits by the IV., I.M., S.C., and oral routes at maximum levels ranging from 12 to 250 times the human dose have demonstrated no impairment of fertility or significant harm to the fetus due to metoclopramide. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Metoclopramide is excreted in human milk. Caution should be exercised when metoclopramide is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established (see <span class="Bold"><a href="#over">OVERDOSAGE</a></span>).</p>
<p>Care should be exercised in administering metoclopramide to neonates since prolonged clearance may produce excessive serum concentrations (see <span class="Bold"><a href="#pharma">CLINICAL PHARMACOLOGY - Pharmacokinetics</a></span>). In addition, neonates have reduced levels of NADH-cytochrome b<span class="Sub">5</span> reductase which, in combination with the aforementioned pharmacokinetic factors, make neonates more susceptible to <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> (see <span class="Bold"><a href="#over">OVERDOSAGE</a></span>).</p>
<p>The safety profile of metoclopramide in adults cannot be extrapolated to pediatric patients. <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonias</span> and other extrapyramidal reactions associated with metoclopramlde are more common in the pediatric population than in adults. (See <span class="Bold"><a href="#warn">WARNINGS</a></span> and <span class="Bold"><a href="#extra">ADVERSE REACTIONS - Extrapyramidal Reactions</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of reglan<span class="Sup">®</span> did not include sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects.</p>
<p>The risk of developing parkinsonian-like side effects increases with ascending dose. Geriatric patients should receive the lowest dose of reglan<span class="Sup">®</span> that is effective. If parkinsonian-like symptoms develop in a geriatric patient receiving reglan<span class="Sup">®</span>, reglan<span class="Sup">®</span> should generally be discontinued before initiating any specific anti-parkinsonian agents (see <span class="Bold"><a href="#warn">WARNINGS</a></span> and <span class="Bold"><a href="#reflux">DOSAGE AND ADMINISTRATION - For the Relief of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux</span></a></span>).</p>
<p>The elderly may be at greater risk for <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> (see <span class="Bold"><a href="#tardive">WARNINGS - <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></a></span>).</p>
<p>Sedation has been reported in reglan<span class="Sup">®</span> users. Sedation may cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> and manifest as oversedation in the elderly (see <span class="Bold"><a href="#clin">CLINICAL PHARMACOLOGY</a>, <a href="#info">PRECAUTIONS -Information for Patients</a></span> and <span class="Bold"><a href="#CNS">ADVERSE REACTIONS - CNS Effects</a></span>).</p>
<p>reglan<span class="Sup">®</span> is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see <span class="Bold"><a href="#renal">DOSAGE AND ADMINISTRATION - Use in Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></span>).</p>
<p>For these reasons, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased renal function, concomitant disease, or other drug therapy in the elderly (see <span class="Bold"><a href="#reflux">DOSAGE AND ADMINISTRATION - For the Relief of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux</span></a></span> and <span class="Bold"><a href="#renal">Use in Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="pspec"></a><a name="section-7.9"></a><p></p>
<h2>Other Special Populations</h2>
<p class="First">Patients with NADH-cytochrome b<span class="Sub">5</span> reductase deficiency are at an increased risk of developing <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> and/or <span class="product-label-link" type="condition" conceptid="4137763" conceptname="Sulfhemoglobinemia">sulfhemoglobinemia</span> when metoclopramide is administered. In patients with G6PD deficiency who experience metoclopramide- induced <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span>, methylene blue treatment is not recommended (see <span class="Bold"><a href="#over">OVERDOSAGE</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adverse"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In general, the incidence of adverse reactions correlates with the dose and duration of metoclopramide administration. The following  reactions have been reported, although in most instances, data do not permit an estimate of frequency:</p>
<p><span class="Bold">CNS Effects</span></p>
<p><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Restlessness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span> occur in approximately 10% of patients receiving the most commonly prescribed dosage of 10 mg q.i.d. (see <span class="Bold"><a href="#precau">PRECAUTIONS</a></span>). <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> with <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> (see <span class="Bold"><a href="#warn">WARNINGS</a></span>) occur less frequently. The incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> is greater at higher doses. There are isolated reports of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span> without clearcut relationship to metoclopramide. Rarely, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> have been reported.</p>
<p><span class="Bold">Extrapyramidal Reactions (EPS)</span></p>
<p>Acute <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>, the most common type of EPS associated with metoclopramide, occur in approximately 0.2% of patients (1 in 500) treated with 30 to 40 mg of metoclopramide per day. Symptoms include involuntary movements of limbs, facial <span class="product-label-link" type="condition" conceptid="4221082" conceptname="Grimaces">grimacing</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyric crisis</span>, rhythmic protrusion of tongue, bulbar type of speech, <span class="product-label-link" type="condition" conceptid="4339090" conceptname="Trismus">trismus</span>, <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonus</span> (<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>-like reactions), and, rarely, <span class="product-label-link" type="condition" conceptid="253321" conceptname="Stridor">stridor</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> possibly due to <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>; ordinarily these symptoms are readily reversed by diphenhydramine (see <span class="Bold"><a href="#warn">WARNINGS</a></span>).</p>
<p>Parkinsonian-like symptoms may include <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>, mask-like facies (see <span class="Bold"><a href="#warn">WARNINGS</a></span>).</p>
<p><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> most frequently is characterized by involuntary movements of the tongue, face, mouth, or jaw, and sometimes by involuntary movements of the trunk and/or extremities; movements may be choreoathetotic in appearance (see <span class="Bold"><a href="#warn">WARNINGS</a></span>).</p>
<p><span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">Motor restlessness</span> (<span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>) may consist of feelings of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, as well as inability to sit still, pacing, foot tapping. These symptoms may disappear spontaneously or respond to a reduction in dosage.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span></span></p>
<p>Rare occurrences of <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (NMS) have been reported. This potentially fatal syndrome is comprised of the symptom complex of <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>, altered consciousness, muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, and <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic dysfunction</span> (see <span class="Bold"><a href="#warn">WARNINGS</a></span>).</p>
<p><span class="Bold">Endocrine Disturbances</span></p>
<p><span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> secondary to hyperprolactlnemia (see <span class="Bold"><a href="#precau">PRECAUTIONS</a></span>). <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> secondary to transient elevation of aldosterone (see <span class="Bold"><a href="#clin">CLINICAL PHARMACOLOGY</a></span>).</p>
<p><span class="Bold">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, acute <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and possible <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> (see <span class="Bold"><a href="#contra">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#precau">PRECAUTIONS</a></span>).</p>
<p><span class="Bold">Gastrointestinal</span></p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and bowel disturbances, primarily <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><span class="Bold">Hepatic</span></p>
<p>Rarely, cases of hepatotoxicity, characterized by such findings as <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and altered liver function tests, when metoclopramide was administered with other drugs with known hepatotoxic potential.</p>
<p><span class="Bold">Renal</span></p>
<p><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span> and <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>.</p>
<p><span class="Bold">Hematologic</span></p>
<p>A few cases of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, or <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, generally without clearcut relationship to metoclopramide. <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span>, in adults and especially with overdosage in neonates (see <span class="Bold"><a href="#over">OVERDOSAGE</a></span>). <span class="product-label-link" type="condition" conceptid="4137763" conceptname="Sulfhemoglobinemia">Sulfhemoglobinemia</span> in adults.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p>A few cases of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, especially in patients with a history of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Rarely, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, including glossal or <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>.</p>
<p><span class="Bold">Miscellaneous</span></p>
<p><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span>. <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">Porphyria</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="over"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Symptoms of overdosage may include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> and extrapyramidal reactions. Anticholinergic or antiparkinson drugs or antihistamines with anticholinergic properties may be helpful in controlling the extrapyramidal reactions. Symptoms are self-limiting and usually disappear within 24 hours.</p>
<p>Hemodialysis removes relatively little metoclopramide, probably because of the small amount of the drug in blood relative to tissues. Similarly, continuous ambulatory peritoneal dialysis does not remove significant amounts of drug. It is unlikely that dosage would need to be adjusted to compensate for losses through dialysis. Dialysis is not likely to be an effective method of drug removal in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> situations.</p>
<p>Unintentional <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> due to misadministration has been reported in infants and children with the use of metoclopramide oral solution. While there was no consistent pattern to the reports associated with these <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, events included <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, extrapyramidal reactions, and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> has occurred in premature and full-term neonates who were given <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of metoclopramide (1 to 4 mg/kg/day orally, intramuscularly or intravenously for 1 to 3 or more days). <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> can be reversed by the intravenous administration of methylene blue. However, methylene blue may cause <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> in patients with G6PD deficiency, which may be fatal (see <span class="Bold"><a href="#pspec">PRECAUTIONS-Other Special Populations</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">Therapy with reglan<span class="Sup">®</span> tablets should not exceed 12 weeks in duration.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="reflux"></a><a name="section-10.1"></a><p></p>
<h2>For the Relief of Symptomatic <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal Reflux</span></h2>
<p class="First">Administer from 10 mg to 15 mg reglan<span class="Sup">®</span> (metoclopramide hydrochloride, USP) orally up to q.i.d. 30 minutes before each meal and at bedtime, depending upon symptoms being treated and clinical response (see <span class="Bold"><a href="#clin">CLINICAL PHARMACOLOGY</a></span> and <span class="Bold"><a href="#usage">INDICATIONS AND USAGE</a></span>). If symptoms occur only intermittently or at specific times of the day, use of metoclopramide in single doses up to 20 mg prior to the provoking situation may be preferred rather than continuous treatment. Occasionally, patients (such as elderly patients) who are more sensitive to the therapeutic or adverse effects of metoclopramide will require only 5 mg per dose.</p>
<p>Experience with <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">esophageal erosions</span> and ulcerations is limited, but healing has thus far been documented in one controlled trial using q.i.d. therapy at 15 mg/dose, and this regimen should be used when lesions are present, so long as it is tolerated (see <span class="Bold"><a href="#adverse">ADVERSE REACTIONS</a></span>). Because of the poor correlation between symptoms and endoscopic appearance of the esophagus, therapy directed at esophageal lesions is best guided by endoscopic evaluation.</p>
<p>Therapy longer than 12 weeks has not been evaluated and cannot be recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>For the Relief of Symptoms Associated with <span class="product-label-link" type="condition" conceptid="4142033" conceptname="Diabetic gastroparesis">Diabetic Gastroparesis</span> (Diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">Gastric Stasis</span>)</h2>
<p class="First">Administer 10 mg of metoclopramide 30 minutes before each meal and at bedtime for two to eight weeks, depending upon response and the likelihood of continued well-being upon drug discontinuation.</p>
<p>The initial route of administration should be determined by the severity of the presenting symptoms. If only the earliest manifestations of diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">gastric stasis</span> are present, oral administration of reglan<span class="Sup">®</span> may be initiated. However, if severe symptoms are present, therapy should begin with metoclopramide injection (consult labeling of the injection prior to initiating parenteral administration).</p>
<p>Administration of metoclopramide injection up to 10 days may be required before symptoms subside, at which time oral administration may be instituted. Since diabetic <span class="product-label-link" type="condition" conceptid="195847" conceptname="Gastroparesis syndrome">gastric stasis</span> is frequently recurrent, reglan<span class="Sup">®</span> therapy should be reinstituted at the earliest manifestation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="renal"></a><a name="section-10.3"></a><p></p>
<h2>Use in Patients with Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Since metoclopramide is excreted principally through the kidneys, in those patients whose creatinine clearance is below 40 mL/min, therapy should be initiated at approximately one-half the recommended dosage. Depending upon clinical efficacy and safety considerations, the dosage may be increased or decreased as appropriate.</p>
<p>See <span class="Bold"><a href="#over">OVERDOSAGE</a></span> section for information regarding dialysis.</p>
<p>Metoclopramide undergoes minimal hepatic metabolism, except for simple conjugation. Its safe use has been described in patients with advanced liver disease whose renal function was normal.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Each white, capsule-shaped, scored reglan<span class="Sup">®</span> tablet (metoclopramide tablets, USP) contains 10 mg metoclopramide base (as the monohydrochloride monohydrate). Available in:</p>
<p>Bottles of 100 tablets (NDC 68220-151-10)</p>
<p>Each green, elliptical-shaped reglan<span class="Sup">®</span> tablet (metoclopramide tablets, USP) contains 5 mg metoclopramide base (as the monohydrochloride monohydrate). Available in:</p>
<p>Bottles of 100 tablets (NDC 68220-150-10)</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Dispense tablets in tight, light-resistant container.</span></p>
<p>Tablets should be stored at controlled room temperature, between 20°C and 25°C (68°F and 77°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br><span class="Bold">ALAVEN<span class="Sup">®</span></span><br>PHARMACEUTICAL LLC<br>Marietta, GA 30062</p>
<p>For Medical Inquiries, call toll-free 1-888-317-0001</p>
<p>www.alavenpharm.com</p>
<p>Rev. 07/2009<br>PCS 9360<br>6-151-10-16-1009</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="medguide"></a><a name="section-13"></a><p></p>
<h1>Medication Guide</h1>
<p class="First"><span class="Bold">REGLAN (REG-lan) Tablets<br>(metoclopramide tablets)</span></p>
<p>Read the Medication Guide that comes with REGLAN before you start taking it and each time you get a refill. There may be new information. If you take another product that contains metoclopramide (such as REGLAN injection, REGLAN ODT, or metoclopramide oral syrup), you should read the Medication Guide that comes with that product. Some of the information may be different. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment.</p>
<p><span class="Bold">What is the most important information I should know about REGLAN?</span></p>
<p>REGLAN can cause serious side effects, including:</p>
<p><span class="Bold">Abnormal muscle movements</span> called <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> (TD). These movements happen mostly in the face muscles. You can not control these movements. They may not go away even after stopping REGLAN. There is no treatment for TD, but symptoms may lessen or go away over time after you stop taking REGLAN.</p>
<p>Your chances for getting TD go up:</p>
<ul class="Disc">
<li>the longer you take REGLAN and the more REGLAN you take. You should not take REGLAN for more than 12 weeks.</li>
<li>if you are older, especially if you are a woman</li>
<li>if you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></li>
</ul>
<p>It is not possible for your doctor to know if you will get TD if you take REGLAN.</p>
<p>Call your doctor right away if you get movements you can not stop or control, such as:</p>
<ul class="Disc">
<li>lip smacking, chewing, or puckering up your mouth</li>
<li>frowning or scowling</li>
<li>sticking out your tongue</li>
<li>blinking and moving your eyes</li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span> of your arms and legs</li>
</ul>
<p>See the section "<a href="#effects">What are the possible side effects of REGLAN?</a>" for more information about side effects.</p>
<p><span class="Bold">What is REGLAN?</span></p>
<p>REGLAN is a prescription medicine used:</p>
<ul class="Disc">
<li>in adults for 4 to 12 weeks to relieve <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> symptoms with <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>) when certain other treatments do not work. REGLAN relieves daytime <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span> after meals. It also helps <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the esophagus to heal.</li>
<li>to relieve symptoms of slow stomach emptying in people with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. REGLAN helps treat symptoms such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, feeling full long after a meal, and loss of appetite. Not all these symptoms get better at the same time.</li>
</ul>
<p>It is not known if REGLAN is safe and works in children.</p>
<p><span class="Bold">Who should not take REGLAN?</span></p>
<p>Do not take REGLAN if you:</p>
<ul class="Disc">
<li>have stomach or intestine problems that could get worse with REGLAN, such as <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, blockage or a tear in the stomach or bowel wall</li>
<li>have an adrenal gland tumor called a <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytoma</span></li>
<li>are allergic to REGLAN or anything in it. See the end of this Medication Guide for a list of ingredients in REGLAN.</li>
<li>take medicines that can cause uncontrolled movements, such as medicines for mental illness</li>
<li>have <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></li>
</ul>
<p><span class="Bold">What should I tell my doctor before taking REGLAN?</span></p>
<p><span class="Bold">Tell your doctor about all your medical conditions</span>, including if you have:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>Parkinson's disease</li>
<li>high blood pressure</li>
<li>kidney problems. Your doctor may start with a lower dose.</li>
<li>liver problems or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. REGLAN may cause your body to hold fluids.</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Your dose of insulin may need to be changed.</li>
<li>breast cancer</li>
<li>you are pregnant or plan to become pregnant. It is not known if REGLAN will harm your unborn baby.</li>
<li>you are breast-feeding. REGLAN can pass into breast milk and may harm your baby. Talk with your doctor about the best way to feed your baby if you take REGLAN.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.</span> REGLAN and some other medicines may interact with each other and may not work as well, or cause possible side effects. Do not start any new medicines while taking REGLAN until you talk with your doctor.</p>
<p><span class="Bold">Especially tell your doctor if you take:</span></p>
<ul class="Disc">
<li>another medicine that contains metoclopramide, such as REGLAN ODT, or metoclopramide oral syrup</li>
<li>a blood pressure medicine</li>
<li>a medicine for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, especially an Monoamine Oxidase Inhibitor (MAOI)</li>
<li>insulin</li>
<li>a medicine that can make you <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>, such as anti-<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> medicine, sleep medicines, and narcotics.</li>
</ul>
<p>If you are not sure if your medicine is one listed above, ask your doctor or pharmacist.</p>
<p>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take REGLAN?</span></p>
<ul class="Disc">
<li>REGLAN comes as a tablet you take by mouth.</li>
<li>Take REGLAN exactly as your doctor tells you. Do not change your dose unless your doctor tells you.</li>
<li>You should not take REGLAN for more than 12 weeks.</li>
<li>If you take too much REGLAN, call your doctor or Poison Control Center right away.</li>
</ul>
<p><span class="Bold">What should I avoid while taking REGLAN?</span></p>
<ul class="Disc">
<li>Do not drink alcohol while taking REGLAN. Alcohol may make some side effects of REGLAN worse, such as feeling <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>.</li>
<li>Do not drive, work with machines, or do dangerous tasks until you know how REGLAN affects you. REGLAN may cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>.</li>
</ul>
<p><span class="Bold">What are the possible side effects of REGLAN?</span></p>
<p><span class="Bold">Reglan can cause serious side effects, including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Abnormal muscle movements.</span> See "<a href="#important">What is the most important information I need to know about REGLAN?</a>"</li>
<li>
<span class="Bold">Uncontrolled <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of your face and neck muscles, or muscles of your body, arms, and legs (<span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>).</span> These <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span> can cause abnormal movements and body positions. These <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> usually start within the first 2 days of treatment. These <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> happen more often in children and adults under age 30.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, and <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</span> Some people who take REGLAN become depressed. You may have thoughts about hurting or killing yourself. Some people who take Reglan have ended their own lives (<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>).</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS).</span> NMS is a very rare but very serious condition that can happen with Reglan. NMS can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and must be treated in a hospital. Symptoms of NMS include: high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, stiff muscles, problems thinking, very fast or uneven heartbeat, and increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>.</span> Symptoms include slight <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, body <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, trouble moving or keeping your balance. If you already have Parkinson's disease, your symptoms may become worse while you are receiving REGLAN.</li>
</ul>
<p><span class="Bold">Call your doctor and get medical help right away if you:</span></p>
<ul class="Disc">
<li>feel depressed or have thoughts about hurting or killing yourself</li>
<li>have high <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, stiff muscles, problems thinking, very fast or uneven heartbeat, and increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></li>
<li>have muscle movements you cannot stop or control</li>
<li>have muscle movements that are new or unusual</li>
</ul>
<p><span class="Bold">Common side effects of Reglan include:</span></p>
<ul class="Disc">
<li>feeling <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span>, tired, dizzy, or exhausted</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></li>
<li><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></li>
<li>trouble sleeping</li>
</ul>
<p>You may have more side effects the longer you take REGLAN and the more REGLAN you take. You may still have side effects after stopping REGLAN. You may have symptoms from stopping (withdrawal) REGLAN such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and feeling dizzy or nervous.</p>
<p>Tell your doctor about any side effects that bother you or do not go away. These are not all the possible side effects of REGLAN.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store REGLAN?</span></p>
<ul class="Disc">
<li>Keep REGLAN at room temperature between 68°F to 77°F (20°C to 25°C).</li>
<li>Keep REGLAN in the bottle it comes in. Keep the bottle closed tightly.</li>
</ul>
<p><span class="Bold">Keep REGLAN and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about REGLAN</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use REGLAN for a condition for which it was not prescribed. Do not give REGLAN to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about REGLAN. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about REGLAN that is written for health professionals. For more information, go to www.alavenpharm.com or call 1-888-317-0001.</p>
<p><span class="Bold">What are the ingredients in REGLAN?</span></p>
<p><span class="Bold">Active ingredient:</span> metoclopramide</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<dl>
<dt> </dt>
<dd>
<span class="Bold">REGLAN 10 mg tablets:</span> magnesium stearate, mannitol, microcrystalline cellulose, stearic acid</dd>
<dt> </dt>
<dd>
<span class="Bold">REGLAN 5 mg tablets:</span> corn starch, D&amp;C yellow 10 aluminum lake, FD&amp;C blue 1 aluminum lake, lactose, microcrystalline cellulose, silicon dioxide, stearic acid</dd>
</dl>
<p>Manufactured for:<br><span class="Bold">ALAVEN<span class="Sup">®</span></span><br>PHARMACEUTICAL LLC<br>Marietta, GA 30062</p>
<p>For Medical Inquiries, call toll-free 1-888-317-0001<br>www.alavenpharm.com</p>
<p>Rev. 07/2009<br>PCS 9360<br>6-151-10-16-1009</p>
<p>Revised July 2009</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PACKAGE LABEL</h1>
<p class="First">REGLAN 10MG LABEL IMAGE</p>
<p><img alt="REGLAN 10MG LABEL IMAGE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=55f1ee88-a455-44ba-b51a-2fcefe8eda65&amp;name=REGLAN%2010MG%20LABEL%20906.jpg"></p>
<p></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REGLAN 		
					</strong><br><span class="contentTableReg">metoclopramide hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-906(NDC:68220-151)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METOCLOPRAMIDE HYDROCHLORIDE</strong> (METOCLOPRAMIDE) </td>
<td class="formItem">METOCLOPRAMIDE HYDROCHLORIDE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">REGLAN;AP;10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-906-30</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16590-906-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16590-906-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017854</td>
<td class="formItem">01/15/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT RX USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT RX USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">repack, relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e1945d1c-e8f5-408c-a904-430a4234b59b</div>
<div>Set id: 55f1ee88-a455-44ba-b51a-2fcefe8eda65</div>
<div>Version: 1</div>
<div>Effective Time: 20100831</div>
</div>
</div> <div class="DistributorName">STAT RX USA LLC</div></p>
</body></html>
